Welcome to
Elusys Therapeutics, Inc.

Elusys is a private, commercial-stage biopharmaceutical company that has achieved US and international licensure in Canada, the UK, and the EU for its lead antibody therapeutic, a medical countermeasure to treat patients following anthrax exposure after a natural or intentional terrorist incident.

elusys-welcome-image
our-products

OUR PRODUCTS

Learn more
our-partners

OUR PARTNERS

About Us

PRESS RELEASES

December 2, 2020

Obiltoxaximab receives marketing authorization from European Commission for the treatment of Inhalation Anthrax

Read more

October 8, 2020

Obiltoxaximab receives positive CHMP opinion for the treatment of Inhalation Anthrax

Read more

August 12, 2020

Elusys Therapeutics receives Health Canada approval for Anthim® for the treatment for Inhalation Anthrax

Read more

April 23, 2018

Elusys receives second delivery order from U.S. government for Anthim®, its treatment for Inhalation Anthrax

Read more

October 10, 2017

Elusys delivers first shipment of ANTHIM®, its treatment for Inhalational Anthrax, to U.S. Government Strategic National Stockpile

Read more

January 24, 2017

Elusys Receives $16.35 Million for Delivery of ANTHIM® to U.S. Government

Read more
View All Press Releases
B. Anthracis Rods

PUBLICATIONS

  • Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of   Inhalational Anthrax Under the US FDA Animal Rule
  • Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity
  • Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre-and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax
View Publications

About Us

About Anthrax

Media Center

Contact Us

Site Map

Privacy

Terms and Conditions

Copyright © 2022 Elusys Therapeutics, Inc. All Rights Reserved.